INFUMEDIUM SIGNALFINANCIAL10-K

InfuSystem showed meaningfully improved profitability with operating income substantially higher year-over-year, while reducing debt and capital expenditures.

The company's operating leverage is clearly working, with gross profit growing 14% while operating income expanded much more dramatically, suggesting strong cost discipline. The simultaneous debt reduction of 18% and lower capital expenditure requirements indicate improved cash generation and financial flexibility.

Comparing 2026-02-27 vs 2025-03-11View on EDGAR →
FINANCIAL ANALYSIS

InfuSystem delivered strong operational improvement with gross profit growing 14% to $80.3M and operating income substantially higher at $11.9M. The company reduced debt by 18% to $19.6M while operating cash flow grew 19% to $24.4M, demonstrating improved cash generation. Capital expenditures declined by nearly half to $560K, suggesting the business requires less reinvestment while generating stronger returns.

FINANCIAL STATEMENT CHANGES
Operating Income
P&L
+73%
$6.9M$11.9M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Interest Expense
P&L
+54.8%
$1.4M$2.2M

Interest expense surged 54.8% — significant debt increase or rising rates materially impacting earnings.

Capital Expenditure
Cash Flow
-48.7%
$1.1M$560K

Capex reduced 48.7% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Operating Cash Flow
Cash Flow
+19.3%
$20.5M$24.4M

Operating cash flow grew 19.3% — strong conversion of earnings to cash, healthy business fundamentals.

Total Debt
Balance Sheet
-17.8%
$23.9M$19.6M

Debt reduced 17.8% — deleveraging strengthens balance sheet and reduces financial risk.

Inventory
Balance Sheet
-17.4%
$6.5M$5.4M

Inventory reduced 17.4% — lean inventory management or demand outpacing supply.

Current Liabilities
Balance Sheet
+14.3%
$17.7M$20.2M

Current liabilities rose 14.3% — increased short-term obligations, watch current ratio.

Gross Profit
P&L
+14.1%
$70.4M$80.3M

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Current Assets
Balance Sheet
+13%
$32.2M$36.3M

Current assets grew 13% — improving short-term liquidity or inventory/receivables build.

LANGUAGE CHANGES
NEW — 2026-02-27
PRIOR — 2025-03-11
ADDED
Many of the factors that will determine these items are beyond our ability to control or predict.
Our lead platform, Patient Services, provides last-mile solutions for clinic-to-home healthcare where the continuing treatment involves complex DME and related services.
Current barriers to entry for potential competitors are created by our: (i) growing number of third-party payer networks under contract, which included nearly 840 t hird-party payer networks as of December 31, 2025; (ii) economies of scale, which allow for predictable reimbursement and less costly purchase and management of the pumps, respectively; (iii) established, long-standing relationships as a provider of pumps to outpatient oncology practices in the U.S.
and Canada that allow for same-day or next-day delivery of pumps; (vi) our team of field-based and traveling biomedical technicians; and (vii) a wide array of pump repair and service capabilities.
In 2025, our Oncology Business generated approximately 87% of our total Patient Services segment net revenues.
+7 more — sign up free →
REMOVED
During the fiscal year ended December 31, 2023, the Company's also operated through its wholly-owned subsidiary First Biomedical, Inc., a Kansas Corporation, which merged into InfuSystem on January 1, 2024.
During the second quarter of 2023, the Company renamed its two operating segments.
Prior to that time, the Patient Services segment was known as Integrated Therapy Services and the Device Solutions segment was known as Durable Medical Equipment Services.
The changes were for marketing purposes only and there were no changes to the operations of either segment.
Our lead platform, Patient Services, provides last-mile solutions for clinic-to-home healthcare where the continuing treatment involves complex Durable Medical Equipment and related services.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →